文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

病毒血症控制良好的人类免疫缺陷病毒(HIV)感染者与可比非HIV人群的严重急性呼吸综合征冠状病毒2感染风险及核衣壳抗体水平相似

Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People With Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV.
PubMed 文献 · J Infect Dis · 2022-01-01

在阿姆斯特丹进行的AGEhIV队列研究中,从2020年9月每6个月检测一次SARS-CoV-2核衣壳抗体,比较HIV阳性和HIV阴性参与者的SARS-CoV-2感染累积发病率及感染后核衣壳抗体水平。结果显示,HIV阳性(99.2%病毒抑制)与HIV阴性参与者的累积发病率分别为13.4%和11.6%(P=.61),感染后核衣壳抗体水平仅与自报发热相关,与HIV状态无关。

要点

  • HIV阳性且病毒抑制、CD4细胞计数充足者的SARS-CoV-2感染风险与HIV阴性可比人群相似。
  • 截至2021年4月,HIV阳性与HIV阴性参与者的SARS-CoV-2累积发病率分别为13.4%和11.6%(P=.61)。
  • 感染后核衣壳抗体水平仅与自报发热相关,与HIV状态无关。

核心结论

  • 病毒血症抑制且CD4细胞计数充足的HIV阳性个体与可比HIV阴性队列相比,SARS-CoV-2感染获得风险相似,感染后SARS-CoV-2核衣壳抗体水平也相似。

研究设计与样本

  • 在阿姆斯特丹正在进行的AGEhIV队列研究中,前瞻性比较HIV阳性和HIV阴性参与者SARS-CoV-2感染发病率及危险因素。
  • 从2020年9月开始,同意的HIV阳性和HIV阴性参与者每6个月使用联合免疫球蛋白(Ig)A/IgM/IgG SARS-CoV-2核衣壳抗体检测评估一次新发SARS-CoV-2感染。
  • 使用互补对数-对数回归评估2020年2月27日至2021年4月30日期间SARS-CoV-2感染的累积发病率及相关危险因素。
  • 在新发SARS-CoV-2感染者中,使用线性回归比较组间核衣壳(N)抗体水平。
  • 研究纳入241名HIV阳性(99.2%病毒抑制)和326名HIV阴性AGEhIV参与者。

主要发现

  • 截至2021年4月,HIV阳性和HIV阴性参与者的SARS-CoV-2累积发病率分别为13.4%和11.6%(P = .61)。
  • 较年轻年龄和非洲来源与新发感染独立相关。
  • 在新发感染者中,仅自报发热与较高N抗体水平相关,HIV状态与N抗体水平无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Within the ongoing AGEhIV Cohort Study in Amsterdam, we prospectively compared the incidence of and risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection between human immunodeficiency virus (HIV)-positive and HIV-negative participants. Moreover, we compared SARS-CoV-2 nucleocapsid antibody levels between participants with incident infection from both groups. METHODS: Starting in September 2020, consenting HIV-positive and HIV-negative participants were assessed every 6 months for incident SARS-CoV-2 infection, using combined immunoglobulin (Ig) A/IgM/IgG SARS-CoV-2 nucleocapsid antibody assay. Cumulative incidence of SARS-CoV-2 infection and associated risk factors were assessed from 27 February 2020 through 30 April 2021, using complementary log-log regression. In those with incident SARS-CoV-2 infection, nucleocapsid (N) antibody levels were compared between groups using linear regression. RESULTS: The study included 241 HIV-positive (99.2% virally suppressed) and 326 HIV-negative AGEhIV participants. The cumulative SARS-CoV-2 incidence by April 2021 was 13.4% and 11.6% in HIV-positive and HIV-negative participants, respectively (P = .61). Younger age and African origin were independently associated with incident infection. In those with incident infection, only self-reported fever, but not HIV status, was associated with higher N antibody levels. CONCLUSIONS: HIV-positive individuals with suppressed viremia and adequate CD4 cell counts had similar risk of SARS-CoV-2 acquisition and similar SARS-CoV-2 N antibody levels after infection compared with a comparable HIV-negative cohort. CLINICAL TRIAL REGISTRATION: NCT01466582.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Verburgh ML, Boyd A, Wit FWNM, et al. Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People With Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV. J Infect Dis. 2022. PMID: 34929034. doi:10.1093/infdis/jiab616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。